Bank of America lowers Perspective Therapeutics (NYSEAMERICAN:CATX) price target to $5.00. August 14, 2026 Key points. * Bank of America lowered Perspective Therapeutics' price target from $6.00 to $5.00 while maintaining a neutral rating; the revised target implies approximately 57% upside from the prior close. * Analyst sentiment remains broadly positive, with eight Buy ratings and one Hold rating producing a "Moderate Buy" consensus and an average price target of $11.56. * Perspective Therapeutics reported a quarterly loss of $0.22 per share, better than the expected $0.25 loss, but revenue was just $0.08 million and the company continues to post substantial losses as it advances its early-stage cancer therapies. * Five stocks we like better than Perspective Therapeutics. Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) had its price target reduced by equities researchers at Bank of America from $6.00 to $5.00 in a report released on Friday,Benzinga reports. The firm presently has a "neutral" rating on the stock. Bank of America's price objective would suggest a potential upside of 56.99% from the company's previous close. Other equities research analysts also recently issued research reports about the stock. BTIG Research reissued a "buy" rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. Wedbush reaffirmed an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. Finally, Piper Sandler reduced their price objective on Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating for the company in a report on Tuesday. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Perspective Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $11.56. Perspective Therapeutics Stock up 2.7%. CATX stock traded up $0.09 on Friday, reaching $3.19. 588,403 shares of the company traded hands, compared to its average volume of 2,325,881. The firm has a fifty day simple moving average of $3.08 and a 200-day simple moving average of $3.94. Perspective Therapeutics has a one year low of $1.96 and a one year high of $6.16. Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. The company had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.09 million. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 44.22%. On average, research analysts forecast that Perspective Therapeutics will post -1.07 EPS for the current fiscal year. Hedge funds weigh in on Perspective Therapeutics. Institutional investors and hedge funds have recently modified their holdings of the company. Portland Investment Counsel Inc. purchased a new stake in Perspective Therapeutics during the second quarter valued at $852,000. Bank of New York Mellon Corp bought a new stake in shares of Perspective Therapeutics during the 2nd quarter valued at about $1,015,000. Taylor & Morgan Wealth Management LLC grew its stake in shares of Perspective Therapeutics by 127.6% during the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company's stock valued at $225,000 after purchasing an additional 37,000 shares during the period. Seven Fleet Capital Management LP purchased a new stake in shares of Perspective Therapeutics during the 1st quarter valued at about $1,581,000. Finally, Avidity Partners Management LP increased its position in shares of Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company's stock valued at $25,228,000 after purchasing an additional 2,839,266 shares during the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors. Key headlines impacting Perspective Therapeutics. Here are the key news stories impacting Perspective Therapeutics this week: * Positive Sentiment: Brookline Capital Markets raised its 2026 loss estimates: Analyst K. Dolliver now expects a loss of $0.25 per share for the third quarter, $0.26 for the fourth quarter and $0.99 for full-year 2026, compared with previous estimates of $0.32, $0.36 and $1.23, respectively. Smaller projected losses may signal improved expectations for operating performance and could support CATX shares. * Neutral Sentiment: Losses are still expected through 2027. Brookline forecasts quarterly losses of $0.26, $0.27, $0.30 and $0.32 for the first four quarters of 2027, totaling a projected $1.14 loss for the year. The estimates highlight that Perspective Therapeutics remains an early-stage, loss-making biotechnology company, with future results dependent on clinical and commercial progress. * Negative Sentiment: Piper Sandler lowered its expectations for the stock price, indicating a less favorable near-term view of CATX's valuation. The available report does not provide the revised target or the specific reasons for the change. Piper Sandler Has Lowered Expectations for Perspective Therapeutics Stock Price About Perspective Therapeutics. Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Perspective Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list. While Perspective Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Perspective Therapeutics announces acceptance of VMT-α-NET data for oral presentation at the ESMO Congress 2026. GlobeNewswire | Perspective Therapeutics, Inc. Today at 9:22am PDT SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) - Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [[212] Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026. | Presenter | Abstract Title | Presentation Details | | Thorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center | Cohort level safety and efficacy results for [[212] Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1-3 | Abstract Number: 2396RO Session Type: Rapid Oral presentation Session Title: Rapid oral: NETs and endocrine tumours Session Date: October 23, 2026 Session Time: 4:15 - 5:45pm CEST / 10:15 - 11:45am EDT Presentation Time: 4:25 - 4:30pm CEST / 10:25 - 10:30am EDT | About [[212]Pb]VMT-α-NET Perspective designed [[212] Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or 2[12]Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [[212] Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT). Interim clinical data from the study, with a data cut-off date of April 17, 2026, were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026. These data included efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and patients in Cohorts 3 and 4 are pending. The Company plans to submit additional data for presentation at future medical conferences in 2026 and 2027. About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope [212] Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity. The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors). The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary [224] Ra/[212] Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company's beliefs that its product candidates address certain unmet medical needs; the Company's expectations regarding regulatory pathways for its product candidates; the Company's expectations regarding its interactions with regulatory agencies and the expected timing thereof; the Company's regional distribution and manufacturing capabilities; and other statements that are not historical fact. The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company's clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company's cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, Newberggraphic undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: This is a paid placement. For further inquiries, please contact GlobeNewswire directly.